The Adalimumab Biosimilar Market Size is valued at 613.28 Million in 2022 and is predicted to reach 3954.75 Million by the year 2031 at a 23.2 % CAGR during the forecast period for 2023-2031.
Adalimumab is a human monoclonal antibody that inhibits tumor necrosis factor (TNF), which is a soluble inflammatory cytokine, to treat autoimmune disorders. Adalimumab binds to TNF-alpha (TNF-), blocking it from activating TNF receptors, which are responsible for autoimmune disorders' inflammatory responses. Adalimumab treats rheumatoid, juvenile idiopathic, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. These can be treated with several biosimilars that have been approved by the EMA (European Medicines Agency) and the Food and Drug Administration (FDA) of the United States (U.S.). About 240 biosimilar candidates are being made for all diseases. The Adalimumab Biosimilar market keeps growing due to more strategic partnerships and acquisitions. Biosimilars also bring down the cost of treatment, which helps patients get the care they need.
It was first discovered by the "phage display" technique which was named 'D2E7'. Furthermore, it experienced the various manufacturing process at BASF Bioresearch Corporation and developed by BASF Knoll. In December 2000, Abbott announced the acquisition of BASF Bioresearch Corporation.
Abbott Laboratories spun off its pharmaceutical division, AbbVie Inc., in January 2013. AbbVie sold Adalimumab under the brand name Humira. The FDA and European Medicines Agency authorised it in 2008 and 2003, respectively. Humira's patent expired in June 2017 in Europe and November 2017 in the US. Biosimilar adalimumab products are being developed by numerous pharmaceutical companies because it is the world's best-selling medicine.
The market for biosimilar adalimumab is anticipated to expand at a high rate throughout the forecast period. Adalimumab is one of the top-selling medications in the world. In addition, the entry of adalimumab biosimilar competitors into the market is anticipated to stimulate the expansion of the worldwide adalimumab biosimilar market. The market for biosimilar Adalimumab continues to expand due to additional strategic collaborations and acquisitions. Biosimilars also reduce the cost of treatment, enabling patients to receive the care they require. During the projected period, the market for biosimilar adalimumab will be propelled by the rising demand for biosimilar pharmaceuticals and the rising demand for cost-effective therapy in low- and middle-income nations.
However, the complex regulatory process for the licencing of biosimilars is the key factor impeding the expansion of the adalimumab biosimilars market. In addition, the measures employed by patent holder businesses to combat biosimilar competition hinder the expansion of the adalimumab biosimilar industry. For example, Abbvie filed a complaint against Boehringer Ingelheim about a biosimilar Humira product.
Market Segmentation
The Adalimuman biosimilar market is segmented into three main segments. First is Product then application and distribution channels. The Product segment has Amjevita, Cyltezo, Hadlima, Yusimry, Hulio, Hymiroz, Abrilada, Exemptia, Adalirel, Cipleumab. Based on application, the global adalimumab biosimilar market is segmented into rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, and psoriasis. The rheumatoid arthritis application segment is expected to grow at a higher pace during the forecast period owing to the increasing incidence and prevalence rate of disease across the globe. Based on distribution channels, the global adalimumab biosimilar market is segmented as hospital pharmacies, online pharmacies and other direct distribution channels.
Competitive Landscape
Some Major Key Players In The Adalimumab Biosimilar Market:
- Amgen,
- Pfizer,
- Sandoz International GmbH,
- Celltrion Healthcare Co., Ltd.,
- Fresenius Kabi,
- Kyowa Hakko Kirin,
- G. Life Sciences,
- Mochida Pharmaceutical,
- Momenta Pharmaceuticals.
- BIOCND
- Baxalta (Shire)
- Organon
- Teva
- Bio-Thera Solutions
- Biocad
- Boehringer Ingelheim
- CinnaGen
- Coherus Biosciences
- Hetero Drugs
- Hisun Pharmaceuticals
- Innovent Biologics
- Neuclone
- Outlook Therapeutics
- Prestige Biopharma
- Reliance Life Sciences
- Samsung Bioepis
- Shanghai Henlius Biotech
- Shanghai Junshi Biosciences
- Torrent Pharmaceuticals
- Zydus Cadila
- Amneal Pharmaceuticals, Inc.
- Hospira Inc.
- Mylan Pharmaceuticals Inc.
- Kashiv BioSciences, LLC
Adalimumab Biosimilar Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 613.28 Million |
|
Revenue Forecast In 2031 |
USD 3954.75 Million |
|
Growth Rate CAGR |
CAGR of 23.2 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, Application, Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Amgen, Pfizer, Celltrion Healthcare Co., Ltd., Sandoz International GmbH, LG Life Sciences, Mochida Pharmaceutical, Fresenius Kabi, Kyowa Hakko Kirin, and Momenta Pharmaceuticals, BIOCND, Baxalta (Shire), Organon, Teva, Bio-Thera Solutions, Biocad, Boehringer Ingelheim, CinnaGen, Coherus Biosciences, Hetero Drugs, Hisun Pharmaceuticals, Innovent Biologics, Neuclone, Outlook Therapeutics, Prestige Biopharma,Reliance Life Sciences, Samsung Bioepis, Shanghai Henlius Biotech, Shanghai Junshi Biosciences, Torrent Pharmaceuticals, Zydus Cadila, Kashiv BioSciences, LLC, Hospira Inc., Mylan Pharmaceuticals Inc., Amneal Pharmaceuticals, Inc., and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
